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Objective: To evaluate factors predictive for relapse in a cohort of adult patients with acute
promyelocytic leukemia monitored by molecular methods during consolidation and during
at  least one month of maintenance therapy.
Methods: The charts and laboratory data of 65 adult patients with acute promyelocytic
leukemia treated according to the International Consortium on Acute Promyelo-
cytic Leukemia 2006 protocol were reviewed. The identiﬁcation of the promyelocytic
leukemia-retinoic acid receptor-alpha gene rearrangement at diagnosis, post-induction, post-
consolidation and during maintenance treatment was performed by qualitative and
quantitative reverse transcription polymerase chain reaction.
Results: Eighty-nine patients were diagnosed with acute promyelocytic leukemia over a
seven-year period and of these 65 were eligible for treatment with the protocol. Among
the  45 patients who received consolidation and maintenance treatment, six (13%) relapsed,
three  of whom presented hematologic and three presented molecular relapse. The ﬁrst
relapses occurred at a median of 39 months. Relapsed patients were from all risk groups
(low, intermediate and high) and both morphological types (M3 and M3variant) were found.
Three of these patients are alive and in molecular remission after salvage treatment. There
were no statistically signiﬁcant differences regarding gender, age, risk group, morphology,
promyelocytic leukemia breakpoint cluster region, use of all-trans retinoic acid, develop-
ment of differentiation syndrome and number of days to complete remission between the
patients who relapsed and those who did not.
Conclusion: Our results reinforce the importance of prolonged monitoring of acute promy-
elocytic leukemia patients using molecular methods to detect relapse early.Please cite this article in press as: Azevedo IF, et al. Molecular and hemato
a cohort study. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016
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Introduction
Once considered a leukemia with poor prognosis, currently by
means of adequate treatment, acute promyelocytic leukemia
(APL) is highly curable, with remission rates of 90% and
disease-free survival at six years of over 80%.1 Despite the
increase in overall survival, cases of relapse still occur and
need to be promptly identiﬁed, thus allowing pre-emptive
treatment in the case of molecular relapses or re-induction
in cases of hematologic relapse.2
The International Consortium on Acute Promyelocytic
Leukemia (IC-APL 2006) aimed to deploy a network of
National and International centers to improve diagnosis,
treatment, monitoring of treatment response and support
therapy and as a consequence the survival of patients with
APL in developing countries. The treatment was based on the
APL 2005 protocol of the Programa Espanhola de Hematologia
(PETHEMA) group, adapted to the reality of the participating
countries (Brazil, Mexico, Chile, Uruguay) with the substitu-
tion of the anthracycline idarubicin for daunorubicin which is
more  affordable and is widely used in the treatment of other
leukemias.3 Of the eight Brazilian centers participating in the
IC-APL, the center of this study is the only representative of
the northeastern region and included almost one third of the
patients of the study.
The recently published results of the IC-APL3 demonstrated
an improvement in early mortality rates and overall survival
compared with historical controls.4 In the present study, a
cohort of patients diagnosed with APL was evaluated for risk
factors associated with relapse.
Methods
Patients
This study retrospectively analyzed 89 adult patients diag-
nosed with APL between January 2007 and August 2014 at the
Hospital of the Fundac¸ão de Hematologia e Hemoterapia de
Pernambuco (Hemope), Recife, Brazil. Clinical and laboratory
data were obtained from the patients’ charts. The project was
approved by the Research Ethics Committee of the institution
(#028/2006) and was conducted after informed consent was
obtained from the patients.
Diagnosis  and  monitoring
The diagnosis was established by clinical, cytomorphological,
immunophenotypic and molecular criteria.5 The identiﬁca-
tion of the promyelocytic leukemia-retinoic acid receptor-alpha
(PML-RAR˛) gene rearrangement was performed by reverse
transcription polymerase chain reaction (nested RT-PCR
and/or RT-qPCR) according to the international BIOMED-1 and
BIOMED-2 protocols.6,7 Samples for RT-qPCR were sent to the
reference laboratory of the IC-APL study in the FaculdadePlease cite this article in press as: Azevedo IF, et al. Molecular and hemat
a cohort study. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016
de Medicina de Ribeirão Preto da Universidade de São Paulo
(FMRP-USP).
Molecular tests were performed using bone marrow
(BM) samples obtained at initial diagnosis, post-induction, 0 1 6;x  x x(x x):xxx–xxx
post-consolidation (after the third course of consolidation)
and during maintenance. Standard monitoring recom-
mended tests every three and six months, respectively,
during maintenance and after treatment for up to two
years.
Deﬁnitions
Complete hematologic remission (CR) and relapse were
deﬁned using conventional criteria.8 Hematologic relapse was
diagnosed based on the presence of >20% blasts or abnormal
promyelocytes in the bone marrow any time after hemato-
logic remission. Molecular remission (MR) was deﬁned as a
negative RT-PCR result of bone marrow cells after the third
and last cycle of consolidation.9 Molecular persistence was
deﬁned as PCR positivity in two consecutive BM samples col-
lected within a minimal interval of 15 days after the end
of consolidation therapy. Molecular relapse was deﬁned as
the reappearance of the PML-RAR˛-speciﬁc band in two con-
secutive BM samples collected at an interval of 15 days
at any time after consolidation therapy.3,10 Arbitrarily, early
relapse was deﬁned as that occurring within two  years after
proven CR and late relapse beyond this period.11 Differen-
tiation syndrome (DS) was deﬁned according to standard
criteria.12,13
Treatment
The standard treatment protocol used was the IC-APL 2006
with patients being categorized according to the risk of
relapse as described elsewhere.3,9,14,15 The treatment options
of the relapsed cases included re-induction with all-trans
retinoic acid (ATRA), chemotherapy and arsenic trioxide
(ATO) followed by stem cell transplantation (SCT) whenever
possible.2,16–18
Statistical  analysis
Statistical analysis was performed using the Stata 12.0 soft-
ware. The t-test was used to compare the groups regarding age,
days to CR, and months of follow up. Fisher’s exact test was
used for categorical variables (gender, risk of relapse, morphol-
ogy and type of transcript). Relative risk (RR) was calculated
with a 95% conﬁdence interval (95% CI). p-Values <0.05 were
considered statistically signiﬁcant.
Results
Eighty-nine patients were diagnosed with APL during the
period and of these, 65 were eligible for treatment using the IC-
APL 2006 protocol. The median age at initial diagnosis of the
relapsed patients was 37.5 years (range: 24–46 years). Hemato-
logic remission was achieved with a median of 32 days (range:
27–56 days).
As the main purpose of this study was to evaluate fac-ologic relapses in adult patients with acute promyelocytic leukemia:
/j.bjhh.2016.09.010
tors predictive for relapse, analysis was restricted to the
45 patients who achieved remission and who were moni-
tored during consolidation and maintenance. Therefore, 20
out of 65 patients were excluded because they died during
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Table 1 – Main features of relapsed patients from a total of 65 cases of acute promyelocytic leukemia of the Fundac¸ão Hemope.
Case Age (years) Gender Risk Morphology Transcript
type
ATRA  in
induction
phase (days)
Hematologic
remission
(days)
Relapse  Salvage
treatment
Status
(months)
Phase Type Place Time
(months)
1 39 M I C bcr1 29 27 PT Late Molecular 35 ATRA + CT + ATO + Auto SCT Death (42)
2 24 F I C bcr2 31 56 Mn Early Hematologic 24 ATRA + ATO Death (44)
3 46 M H C bcr1 29 32 PT Late Molecular 48 ATO + Auto SCT Death (71)
4 36 M L C bcr3 30 26 PT Late Molecular 43 ATRA + CT + ATO + Auto SCT Alive (64)
5 29 F H C bcr1 32 31 Mn Early Hematologic 21 ATRA + ATO + Auto SCT Alive (28)
6 40 M H V bcr1 27 44 PT Late Hematologic 47 ATRA + ATO Alive (49)
M: male; F: female; L: low; I: intermediate; H: high; C: LMA-M3 classical; V: LMA-M3 variant; PT: post treatment; Mn: maintenance; ATO: arsenic trioxide; ATRA: all-trans retinoic acid; auto SCT:
autologous stem cell transplantation; CT: chemotherapy.
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Table 2 – Analysis of 45 patients with acute promyelocytic leukemia treated at Fundac¸ão Hemope considering the
cumulative incidence of relapse.
Variable All (n = 45) No relapse (n = 39) Relapse (n = 6) RR (95% CI) p-Value
Gender
Female 22 20 (91%) 2 (9%) 1 –
Male 23 19 (83%) 4 (17%) 1.91 (0.39–9.41) 0.413
Age (years)
≤40 33 29 (88%) 4 (12%) 1 –
>40 12 10 (83%) 2 (17%) 1.37 (0.29–6.57) 0.692
Relapse risk
Low/intermediate 31 28 (90%) 3 (10%) 1 –
High 14 11 (79%) 3 (21%) 2.21 (0.51–9.63) 0.283
Morphology
Classical 43 37 (88%) 5 (12%) 1 –
Variant 3 2 (67%) 1 (33%) 2.80 (0.46–16.9) 0.291
Transcript type
bcr1/bcr2 30 25 (83%) 5 (17%) 1 –
bcr3 14 13 (93%) 1 (7%) 0.43 (0.05–3.33) 0.391
ATRA in induction phase (days)
≤30 32 29 (91%) 3 (9%) 1 –
>30 13 10 (77%) 3 (23%) 2.46 (0.57–10.6) 0.220
Differentiation syndrome
No 33 28 (85%) 5 (15%) 1 –
Yes 12 11 (92%) 1 (8%) 0.55 (0.07–4.24) 0.552
Hematologic remission (days)
≤30 14 11 (79%) 3 (21%) 1 –
>30 31 28 (90%) 
RR: relative risk; CI: cumulative incidence.
induction or consolidation. Six patients out of 45 (13%) pre-
sented molecular (three) or hematologic (three) relapse. The
ﬁrst relapse among the patients occurred at a median of
39 months (range: 21–48 months) following initial treatment.
Median follow-up of the six patients from diagnosis was 46.5
months (range: 28–71 months) and mean number of sequen-
tial samples analyzed during monitoring was 12 per patient
(range: 5–21 months).
The main features of the six relapsed cases are shown in
Table 1. Four patients achieved MR  after salvage treatment and
were subjected to autologous (auto)-SCT (Cases 1, 3, 4 and 5);
two of these are alive and in MR.  One patient (Case 6) was in
consolidation phase of the treatment until the closing of this
article.
Two patients had a second relapse, one patient (Case 2)
twelve months after the ﬁrst hematologic relapse while in
salvage treatment waiting for auto-SCT. This patient had no
human leukocyte antigen (HLA)-compatible donor and was
treated with ATO without achieving a third remission. The
other patient (Case 1) presented a second hematologic relapse
fourteen months after the ﬁrst molecular relapse. He was sub-
mitted to ATO treatment followed by auto-SCT, but relapsed 3
months later and died.
Table 2 shows the main clinical and laboratorial features of
patients with or without relapse. No signiﬁcant difference wasPlease cite this article in press as: Azevedo IF, et al. Molecular and hemat
a cohort study. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016
observed between the two groups of patients regarding gender,
age, risk of relapse, morphology, PML  breakpoint, duration of
ATRA treatment during induction, frequency of evolution of
DS and number of days to CR.3 (10%) 0.45 (0.10–1.96) 0.283
Discussion
The 13% incidence of relapse in this study with 45 patients
from a single center is consistent with other works. Cassinat
et al.19 reported a relapse rate of 14.6% among 260 patients
with APL in a multicenter study in France. Moreover, Karim
et al.20 in a study with 26 patients, found a 11.5% relapse rate of
both molecular and of the central nervous system (CNS). In the
matched-pair analyses of the PETHEMA LPA-2005 and IC-APL-
2006 studies,21 relapse rates were 7.4% and 5%,  respectively. No
CNS relapse was detected in this series. All PETHEMA/Gruppo
Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA)
risk groups were represented among relapsed patients with
proportions similar to other studies.22,23 The only patient with
low risk for relapse had a bcr3 PML  variation which is consid-
ered of adverse prognostic factor.24
The results of this study are consistent with published data
regarding age and gender of the relapsed APL patients.11,22
Both morphological types (M3 and M3v) were found among
relapsed patients. In one of the three cases of hematologic
relapse, there was a change in morphology from variant (M3v)
to classical type (M3). Morphological changes at relapse in
APL may not be a rare event, and the leukemic cells can
show variable morphological features at the time of relapse,
which could result in misdiagnosis as a different type of acuteologic relapses in adult patients with acute promyelocytic leukemia:
/j.bjhh.2016.09.010
myeloid leukemia as pointed out by Yoshii et al.23 This author
recommends a comprehensive approach to the diagnosis and
appropriate treatment of relapsed APL.
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The overall incidence of DS reported in the LPA series
aries from 7.8% to 48%.25,26 In the current series, one case,
hat presented with DS during the initial treatment, suffered
ematologic relapse but is alive. The European APL Group
eported an increased risk of relapse independent of white
lood cell count in patients developing DS.27 Thépot et al.28
uggested that the total duration of treatment with ATRA of
ess than 21 days during the induction phase was associated
ith greater rates of relapse of leukemia. In this series, all
atients who  relapsed were treated with ATRA for more  than
1 days with an average of 30 days.27–29 No case of resis-
ance to ATRA was identiﬁed as all treated patients achieved
emission.
Current studies have shown high rates of hematologic
elapse compared to molecular relapse.3,11,22 In the current
eries, three relapses were molecular and three hematologic.
olecular monitoring of the PML-RAR  ˛ transcript is useful
o anticipate overt hematologic relapse10 with the IC-APL
006 protocol recommending tests every three months for at
east two years after completing treatment.3 This approach is
mportant because the majority of the relapses in this study
ccurred during this period with a median of 44.5 months. In
his regard, two cases of hematologic relapse in this series did
ot strictly follow the monitoring protocol. Although the mean
umber of samples analyzed per patient was higher than that
eported by Cassinat et al.,19 who analyzed an average of six
amples per patient (range: 1–28), there is a need for more
trict monitoring.
Proposed modalities of therapy in the salvage setting for
PL patients includes treatment or retreatment with ATRA,
TO, or both, cytotoxic chemotherapy, auto or allogeneic SCT
nd enrollment in a clinical trial.2,16–18,29 Patients treated with
alvage chemotherapy alone have lower survival compared
o those submitted to SCT.17 Auto-SCT should be performed
hen the patient achieves MR,  but may increase the risk of a
ew relapse. Patients submitted to auto-SCT have higher rates
f overall and disease-free survival than those who undergo
llogeneic SCT.17 Allogeneic SCT is indicated when the patient
oes not achieve molecular response after consolidation.
hese patients seem to have more  prolonged remissions and
ess incidence of new relapse, but a higher death rate due to
raft-versus-host disease (GVHD).
The protocol for relapsed patients included ATRA and
darubicin plus ATO followed by auto-SCT, after conﬁrmation
f the MR.  Four patients did not receive anthracycline due
o clinical conditions, including one patient who had a heart
ttack at the time the relapse was diagnosed.
The IC-APL 2006 protocol used in the present study
igniﬁcantly reduced early mortality and improved the over-
ll survival of APL patients3 when compared to historical
ontrols.4 Increased knowledge of the outcome in the sub-
opulation of treated patients that exhibit relapse is crucial
o understanding the pathophysiology of APL and to improve
urvival.22 In the real-world circumstances of the health-
are delivery system, costs and availability become issues for
atients and clinicians, and show the importance of singlePlease cite this article in press as: Azevedo IF, et al. Molecular and hemato
a cohort study. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016
enter results. This study is the ﬁrst to report on molecular
nd hematologic relapse in a cohort of Brazilian APL patients
ubmitted to the IC-APL 2006 protocol. 1 6;x x x(x x):xxx–xxx 5
Conclusion
There were no differences in clinical-biological variables
between patients with or without relapse. The data of this
study also show the efﬁcacy of the treatment protocol used for
APL and the importance of prolonged monitoring using molec-
ular methods to detect relapse earlier in order to improve
survival of this subgroup of patients.
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